Visterra, Inc.

Andrew M Wollacott

Karthik Viswanathan

Boopathy Ramakrishnan

Zachary Shriver

Gregory Babcock

James R Myette

Hedy Adari-Hall

Brian Booth

Obadiah Joseph Plante

James C Delaney

Lauren Olinski

Susan Sloan

Kristin Narayan

Bharat Chaganty

Hamid Tissire

Kenneth Douglas Johnson

Tyree J Koch

Jose Miguel Trevejo

Kai Li

Maciej Boni

Zachary Holmes Shriver

Antibody molecules that specifically bind to C5aR1 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as ANCA-vasculitis.

Antibody molecules to C5AR1 and uses thereof

Humanized antibody molecules that specifically bind to CD138 are disclosed. The humanized antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as multiple myeloma.

Humanized antibody molecules to CD138 and uses thereof

The present disclosure provides, among other things, two different formats of humanized antibodies against human complement component 5a receptor I. The disclosure also provides a method of treating a subject having dysfunctions of C5a/C5aR1 axis pathway, including but not limited to ANCA-associated vasculitis, comprising administering to the subject in need thereof an effective amount of antibody or a nucleic encoding an antibodies binding to C5aR1 described herein, and wherein administering results in a decrease in symptoms associated with C5a/C5aR1 associated dysfunction in the subject.

Humanized complement 5a receptor 1 antibodies and methods of use thereof

Humanized complement 5A receptor 1 antibodies and methods of use thereof

Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy.

Method of using antibody molecules to detect a proliferation-inducing ligand (APRIL)

Antibody molecule-drug conjugates (ADCs) that specifically bind to lipopolysaccharides (LPS) are disclosed. The antibody molecule-drug conjugates can be used to treat, prevent, and/or diagnose bacterial infections and related disorders.

Antibody molecule-drug conjugates and uses thereof

The present disclosure provides, among other things, two different formats of humanized antibodies against human complement component 5a receptor I. The disclosure also provides a method of treating a subject having dysfunctions of C5a/C5aR1 axis pathway, including but not limited to ANCA-associated vasculitis, comprising administering to the subject in need thereof a an effective amount of antibody or a nucleic encoding an antibodies binding to C5aR1 described herein, and wherein administering results in a decrease in symptoms associated with C5a/C5aR1 associated dysfunction in the subject.

Polypeptides, such as antibody molecules and fusion proteins, comprising an Fc region, are disclosed. The polypeptides can be used to treat, prevent, and/or diagnose disorders.

Engineered polypeptides and uses thereof

Antibody molecules to C5aR1 and uses thereof

Methods of treating IgA nephropathy by administering an anti-APRIL (a proliferation-inducing ligand) antibody molecule

Nucleic acid molecules encoding antibodies to a proliferation-inducing ligand (APRIL)

Antibody molecules to a proliferation-inducing ligand (APRIL)

Growing community of inventors

Milton, MA, United States of America

Andrew M Wollacott